OrbiMed’s MyoKardia, Inc. Common Stock MYOK Stock Holding History

OrbiMed’s Portfolio MYOK Stock Details MYOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-27,900	Closed	-$2.03M	–	167
2019 Q4	$2.03M	Sell	27,900 -755,132	-96%	-$45.8M	0.03%	118
2019 Q3	$40.8M	Sell	783,032 -172,268	-18%	-$9.16M	0.77%	42
2019 Q2	$47.9M	Buy	955,300 +48,700	+5%	+$2.37M	0.74%	41
2019 Q1	$47.1M	Buy	906,600 +571,500	+171%	+$26.3M	0.73%	41
2018 Q4	$16.4M	Buy	+335,100	New	+$18.4M	0.3%	74

Other funds holding MYOK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

OrbiMed's MYOK Position: Q1 2020 in Review

OrbiMed sold out of MyoKardia, Inc. Common Stock (MYOK) in Q1 2020, closing a stake of 27,900 shares — an estimated $2.03M sold.

OrbiMed first reported a position in MYOK in Q4 2018 and held it in 5 quarters. The position peaked at $47.9M in Q2 2019. 194 funds tracked by Wall St. Rank hold MYOK as of Q1 2020.

OrbiMed reported no remaining MyoKardia, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
OrbiMed sold 27,900 MyoKardia, Inc. Common Stock shares in Q1 2020, an estimated $2.03M.
OrbiMed first reported a position in MyoKardia, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
OrbiMed's MyoKardia, Inc. Common Stock position peaked at $47.9M in Q2 2019.
194 funds tracked by Wall St. Rank held MyoKardia, Inc. Common Stock as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.